L. Choi

发表

Pharmacokinetics of enteric‐coated mycophenolate sodium in stable pediatric renal transplant recipients

R. Schmouder, Wei Zhu, W. Niederberger, 2005, Pediatric transplantation.

Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM 486 A in Combination with 5-Fluorouracil / Leucovorin in Metastatic Colorectal Cancer

J. Ledermann, J. Verweij, J. Bridgewater, 2004 .

Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer

J. Ledermann, J. Verweij, L. van Zuylen, 2004, Clinical Cancer Research.

A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours

H. Groen, R. Paridaens, A. Oosterom, 2000, British Journal of Cancer.

Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro.

F. Picard, M. Azria, P. J. Swart, 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.

M. Hidalgo, G. Weiss, D. V. Von Hoff, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Influence of food intake on the bioavailability and efficacy of oral calcitonin.

M. Karsdal, C. Christiansen, B. Riis, 2009, British Journal of Clinical Pharmacology.

Effect of Renal Function on the Pharmacokinetics of Valsartan

Angelito A. Bernardo, A. Lau, S. Mangat, 1997 .

Effects of chronic nicotine administration and age on various neurotransmitters and associated enzymes in male Fischer-344 rats.

S. Butcher, C. Su, M. Simon, 1974, Toxicology and applied pharmacology.

A Phase I and Pharmacokinetic Study of SAM 486 A , a Novel Polyamine Biosynthesis Inhibitor , Administered on a Daily-times-five every-three-week Schedule in Patients with Advanced Solid Malignancies 1

M. Hidalgo, G. Weiss, G. Clark, 2002 .

Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

E. Thiel, B. Coiffier, R. Herrmann, 2004, Clinical Cancer Research.

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

A. Harris, J. Foekens, J. Wood, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.

J. Wanders, J. Verweij, L. Denis, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.

A. Harris, J. Verweij, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

The polyamine synthesis inhibitor SAM486A in combination with 5-FU/LV in metastatic colorectal cancer (MCC): results of a phase I and pharmacokinetic study

J. Ledermann, J. Verweij, J. Bridgewater, 2000 .

The absence of a pharmacokinetic interaction between aspirin and the angiotensin‐converting enzyme inhibitor benazepril in healthy volunteers

A. Sioufi, V. John, J. Godbillon, 1994, Biopharmaceutics & drug disposition.

Intraindividual variability in theophylline pharmacokinetics in subjects with mild/moderate asthma.

E. Middleton, R. Slaughter, L. Choi, 1987, The Journal of allergy and clinical immunology.

Clinical Pharmacology of Lumiracoxib

C. Rordorf, J. Mangold, P. Marshall, 2005, Clinical pharmacokinetics.

Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers

J. Verweij, Honghui Zhou, R. Capdeville, 2000, Journal of clinical pharmacology.

A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid

C. Twelves, J. Cassidy, M. Devlin, 2004, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetic Analysis of Dexmedetomidine in Children using Real-World-Data Obtained from Electronic Health Records and Remnant Clinic Samples

P. Kannankeril, S. V. Van Driest, N. James, 2021, medRxiv.

Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium.

W. Arns, R. Schmouder, C. Yeh, 2006, International journal of clinical pharmacology and therapeutics.

Effects of Last Dosing Time on Population Pharmacokinetic Analysis of Tacrolimus Performed using Extracted Data from Electronic Health Records

C. Beck, H. Weeks, M. Williams, 2021, medRxiv.

Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.

H. Tedesco-Silva, C. Felipe, R. Schmouder, 2005, Transplantation proceedings.

Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer

J. Ledermann, J. Verweij, L. van Zuylen, 2004, Clinical Cancer Research.